Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference43 articles.
1. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) – Annex I – Definitions (Rev 4). 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf Accessed 04 Dec 2021.
2. Amare GG, Meharie BG, Belayneh YM. A drug repositioning success: the repositioned therapeutic applications and mechanisms of action of thalidomide. J Oncol Pharm Pract. 2021;27(3):673–8. https://doi.org/10.1177/1078155220975825.
3. Clinical Trials [database on the Internet]. U.S. National Library of Medicine. 2021. Available from: https://clinicaltrials.gov/. Accessed: 06 Jan 2021.
4. Sundaresan L, Giri S, Singh H, Chatterjee S. Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: hints on molecular action. Br J Clin Pharmacol. 2021. https://doi.org/10.1111/bcp.14792.
5. Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34(4):1197–201. https://doi.org/10.1038/s41375-019-0620-8.